T-cell therapy for resistant viral infections after transplant or cancer treatment
Part of Infections clinical trials.
This trial tests a special T-cell treatment (LB-DTK-MV) for people with virus infections (CMV, BKV, EBV) that did not get better with standard medicines. It is for patients who had a stem cell transplant or certain cancer therapies like CAR-T or bispecific antibodies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older
- You had a stem cell transplant or received CAR-T therapy (like Kymriah or Yescarta) or a bispecific antibody (like Glofitamab or Teclistamab)
- You have a CMV, BKV, or EBV infection that has not responded to standard antiviral treatment
- You are able to lower your steroid dose to a small amount (0.5 mg/kg/day of prednisolone or less)
- You have enough healthy blood cells (hemoglobin ≥ 8.0 g/dL) and a working immune system (neutrophil count ≥ 500 for 3 days after transplant)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether specially trained immune cells (virus-specific T cells) can safely treat stubborn viral infections after a stem cell transplant. It focuses on children and young adults who have not responded to standard antiviral treatments.
This Phase 1 study tests an “off-the-shelf” type of immune cell therapy made to attack several viruses (EBV, CMV, adenovirus, and BK, and possibly JC) in people who had an allogeneic stem cell transplant and still have ongoing viral infection. It may help your body control the virus when standard treatments have not worked or you cannot tolerate them.
This trial tests a treatment using specially grown T-cells (a type of immune cell) to fight certain viruses that won't go away with standard medicines. It is for people who have had a stem cell or organ transplant, or who have a weak immune system, and who are struggling with adenovirus, CMV, or EBV infections.
This trial tests whether specially prepared donor immune cells can fight stubborn viral infections that did not get better with standard treatment. It is for people who have had a stem cell transplant and are still struggling with viruses like CMV, EBV, or others.
This trial tests a special immune cell treatment (R-MVST cells) for children and young adults who have had a stem cell or organ transplant and are fighting stubborn viral infections like EBV, CMV, ADV, or BK virus. The goal is to see if these cells can help control the viruses when standard medicines haven't worked well enough.
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
Hear when a new BKV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.